[Progress of researches on the antiparasitic activity of antimicrobial peptide LL-37]

Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2024 Mar 25;36(1):98-104. doi: 10.16250/j.32.1374.2023157.
[Article in Chinese]


Parasitic diseases caused by protozoan and helminth infections are still widespread across the world, notably in tropical and subtropical areas, which threaten the children and adult health. Long-term use of anti-parasitic drugs may result in reduced drug susceptibility and even drug resistance. Antimicrobial peptides have been demonstrated to inhibit parasite growth and development, which has potential antiparasitic values. LL-37, the only human antimicrobial peptide in the cathelicidin family, has been widely investigated. This paper reviews the progress of researches on the antiparasitic activity of LL-37, and discusses the prospects of LL-37 in the research of parasites.

[摘要] 由原虫、蠕虫感染导致的寄生虫病在全球范围内广泛流行, 尤其是在热带和亚热带地区, 对儿童和成人生命健 康均造成威胁。抗寄生虫药的长期使用导致寄生虫对药物敏感性下降甚至出现耐药性。研究表明抗菌肽可抑制寄生虫 生长发育, 具有潜在抗寄生虫价值, 其中LL-37作为组织蛋白酶抑制素 (cathelicidin) 家族中唯一的人源抗菌肽被广泛研 究。本文综述了LL-37抗寄生虫作用的研究进展, 并对其作为抗寄生虫药物的候选资源的应用前景进行了探讨。.

Keywords: Human antimicrobial peptide; LL-37; Mechanism of action; Parasite.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Antimicrobial Cationic Peptides* / pharmacology
  • Antimicrobial Cationic Peptides* / therapeutic use
  • Cathelicidins / pharmacology
  • Humans


  • Antimicrobial Cationic Peptides
  • Cathelicidins